Trial Profile
Daratumumab-Based Maintenance in Patients With Relapsed Multiple Myeloma After Salvage Autologous Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Busulfan; Gemcitabine; Melphalan; Panobinostat; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Feb 2024 Planned End Date changed from 1 Sep 2024 to 23 Apr 2025.
- 19 Feb 2024 Planned primary completion date changed from 1 Sep 2024 to 23 Apr 2025.
- 05 Oct 2023 Status changed from discontinued to active, no longer recruiting.